Take home points: Empagliflozin has a large study that shows a small but significant reduction in death and heart failure hospitalizations (NNT for primary outcome = 63 patients for ~3 years) compared to placebo in patients with diabetes and CV disease Empagliflozin can cause urinary and genital infections and ketoacidosis with near normal glucose Because of its mechanism (spilling glucose through the urine), it may develop a role in diabetes mellitus type 1 Refrences: American Diabetes Association: Standards of medical care in diabetes - 2016
Pharmaceutical Biotechnology
Amouzegar A, Wu X, Long JP, Chen GW, Wong JW, Prabhakaran S, Little L, Gumbs C, Bota N, Malke J, Simon J, Zhang J, Nagarajan P, Davies MA , Tawbi H, Amaria RN, Oliva ICG, Ikeguchi AP, Su S, Hanna EY, Weiser R, Bednarski B, Sims TT, Mitra D, Wargo J, Gershenwald JE, Scheet P, Yu Y, Huff C, Nelson KC, McQuade JL, Futreal PA
However, a well-formulated serum may give you results in 3-5 days as well
Another potential limitation of the study according to the AAOph and the North American Neuro-Ophthalmology Society was that all patients included were seen at Massachusetts Eye and Ear in Boston
Infliximab treatment of rheumatoid arthritis
